Absorption of epi-doxorubicin after intravesical administration of patients with in situ transitional cell carcinoma of the bladder

K. Mross, P. Maessen, W. J F Van Der Vijgh, J. F. Bogdanowicz, K. H. Kurth, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Nine patients with in situ bladder cancer (TIS) were treated by intravesical instillation of epi-doxorubicin (epi-DOX). The amount of anthracycline in 1 ml plasma was in the nanogram range. 78.9 ± 12.0% and 84.2 ± 10.6% of the administered dose (30 and 50 mg, respectively) could be recovered.

Original languageEnglish (US)
Pages (from-to)505-508
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number5
DOIs
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Absorption of epi-doxorubicin after intravesical administration of patients with in situ transitional cell carcinoma of the bladder'. Together they form a unique fingerprint.

  • Cite this